山大地緯(688579.SH):目前公司具備完整的DRG/DIP解決方案
格隆匯7月26日丨山大地緯(688579.SH)在投資者互動平台表示,目前公司具備完整的DRG/DIP解決方案,包括數據採集質控、分組計算、基金結算、考核評價、費用監管等,自主研發了DRG/DIP運營分析管理平台。當前,公司服務多地的DRG/DIP支付方式改革業務,有力保障醫保支付方式改革的落地運行。公司積極響應《國家醫療保障局辦公室關於印發按病組(DRG)和病種分值(DIP)付費2.0版分組方案並深入推進相關工作的通知》要求,形成地緯DRG/DIP2.0完整解決方案,服務各地醫保部門完成DRG/DIP付費2.0版上線,為公司在醫保醫療領域的持續快速發展增添動力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.